Dic(17;18)(p11.2;p11.2) is a recurring abnormality in chronic lymphocytic leukaemia associated with aggressive disease
暂无分享,去创建一个
Jeffrey A Jones | J. Byrd | N. Heerema | K. Blum | L. Andritsos | J. Flynn | A. Stark | John Zhao | J. Woyach | A. McFaddin | T. Lin
[1] J. Byrd,et al. Chronic lymphocytic leukemia. , 2010, Hematology. American Society of Hematology. Education Program.
[2] A. Hagemeijer,et al. Chromosomal translocations independently predict treatment failure, treatment-free survival and overall survival in B-cell chronic lymphocytic leukemia patients treated with cladribine , 2007, Leukemia.
[3] John C Reed,et al. Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: results from the US Intergroup Phase III Trial E2997. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] Sainan Wei,et al. Loss of 17p is a major consequence of whole-arm chromosome translocations in hematologic malignancies. , 2007, Cancer genetics and cytogenetics.
[5] K. Stamatopoulos,et al. Clinical, immunophenotypic, and molecular profiling of trisomy 12 in chronic lymphocytic leukemia and comparison with other karyotypic subgroups defined by cytogenetic analysis. , 2006, Cancer genetics and cytogenetics.
[6] Tait D. Shanafelt,et al. Loss of TP53 is due to rearrangements involving chromosome region 17p10∼p12 in chronic lymphocytic leukemia , 2006 .
[7] M. Caligiuri,et al. Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: justification for risk-adapted therapy. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] F. Ajchenbaum‐Cymbalista,et al. Binet's staging system and VH genes are independent but complementary prognostic indicators in chronic lymphocytic leukemia. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] S. Knuutila,et al. More extensive genetic alterations in unmutated than in hypermutated cases of chronic lymphocytic leukemia , 2003, Genes, chromosomes & cancer.
[10] L. Shaffer,et al. Genome architecture catalyzes nonrecurrent chromosomal rearrangements. , 2003, American journal of human genetics.
[11] D. Neme,et al. Cytogenetic, FISH, and molecular studies in a case of B‐cell chronic lymphocytic leukemia with karyotypic evolution , 2002, European journal of haematology.
[12] Axel Benner,et al. Stromal-derived factor 1 inhibits the cycling of very primitive human hematopoietic cells in vitro and in NOD/SCID mice. , 2002, Blood.
[13] D. Oscier,et al. Multivariate analysis of prognostic factors in CLL: clinical stage, IGVH gene mutational status, and loss or mutation of the p53 gene are independent prognostic factors. , 2002, Blood.
[14] A Benner,et al. Genomic aberrations and survival in chronic lymphocytic leukemia. , 2000, The New England journal of medicine.
[15] F. Solé,et al. Dicentric (17;18) in a case of atypical B-cell chronic lymphocytic leukemia. , 2000, Cancer genetics and cytogenetics.
[16] J. Benichou,et al. Expression of unmutated VH genes is a detrimental prognostic factor in chronic lymphocytic leukemia. , 2000, Blood.
[17] T J Hamblin,et al. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. , 1999, Blood.
[18] N. Chiorazzi,et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. , 1999, Blood.
[19] G. Salles,et al. Translocations involving the short arm of chromosome 17 in chronic B-lymphoid disorders: frequent occurrence of dicentric rearrangements and possible association with adverse outcome , 1999, Leukemia.
[20] F. Mancini,et al. p53 expression in B-cell chronic lymphocytic leukemia: a marker of disease progression and poor prognosis. , 1998, Blood.
[21] A Benner,et al. p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias. , 1995, Blood.
[22] B. Quesnel,et al. p53 Mutations Are Associated With Resistance to Chemotherapy and Short Survival in Hematologic Malignancies , 1994 .
[23] C. Preudhomme,et al. Mutations of the p53 gene in B-cell chronic lymphocytic leukemia: a report on 39 cases with cytogenetic analysis. , 1992, Leukemia.
[24] S. Knuutila,et al. Prognostic subgroups in B-cell chronic lymphocytic leukemia defined by specific chromosomal abnormalities. , 1990, The New England journal of medicine.
[25] Mark J. Thomas,et al. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis , 1981, Cancer.
[26] L. Shaffer,et al. ISCN 2009 - An International System for Human Cytogenetic Nomenclature , 2009 .
[27] Daniel L Van Dyke,et al. Loss of TP53 is due to rearrangements involving chromosome region 17p10 approximately p12 in chronic lymphocytic leukemia. , 2006, Cancer genetics and cytogenetics.
[28] B. Quesnel,et al. p53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies. , 1994, Blood.
[29] P. Nowell,et al. Cytogenetic Findings and Survival in B-cell Chronic Lymphocytic Leukemia. Second IWCCLL Compilation of Data on 662 Patients. , 1991, Leukemia & lymphoma.
[30] Iscn. International System for Human Cytogenetic Nomenclature , 1978 .
[31] D C Case,et al. Clinical staging of chronic lymphocytic leukemia. , 1977, The Journal of the Maine Medical Association.